Anti-interleukin-17A biologics for the long-term treatment of bullous pemphigoid: A prospective, cohort study
J Eur Acad Dermatol Venereol
.
2023 Jun;37(6):e749-e751.
doi: 10.1111/jdv.18907.
Epub 2023 Jan 31.
Authors
K Bakirtzi
1
,
E Sotiriou
1
,
I Papadimitriou
1
,
E Vakirlis
1
,
F S Delli
2
,
D Ioannides
1
Affiliations
1
First Department of Dermatology and Venereology, Aristotle University of Thessaloniki, Thessaloniki, Greece.
2
State Dermatology Department, Hippokratio General Hospital of Thessaloniki, Thessaloniki, Greece.
PMID:
36688248
DOI:
10.1111/jdv.18907
No abstract available
Publication types
Letter
MeSH terms
Biological Products* / therapeutic use
Cohort Studies
Humans
Pemphigoid, Bullous* / drug therapy
Prospective Studies
Substances
Biological Products
IL17A protein, human